Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for ROBERT EDWARDS�
+0.86 (1.07%)
Apr 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 79.26 - 81.69
52 week 60.62 - 86.11
Open 80.01
Vol / Avg. 2.13M/1.42M
Mkt cap 8.72B
P/E 23.72
Div/yield     -
EPS 3.43
Shares 107.24M
Beta 0.47
Inst. own 95%
May 8, 2014
Edwards Lifesciences Annual Shareholder Meeting - 1:00PM EDT - Add to calendar
Apr 24, 2014
Q1 2014 Edwards Lifesciences Earnings Conference Call - 5:00PM EDT - Add to calendar
Apr 24, 2014
Q1 2014 Edwards Lifesciences Earnings Release - 4:00PM EDT - Add to calendar
Feb 3, 2014
Q4 2013 Edwards Lifesciences Earnings Conference Call
Feb 3, 2014
Q4 2013 Edwards Lifesciences Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 14.14% 19.15%
Operating margin 18.94% 25.19%
EBITD margin - 25.61%
Return on average assets 11.57% 15.84%
Return on average equity 20.29% 25.78%
Employees 8,600 -
CDP Score - -


One Edwards Way
IRVINE, CA 92614
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
Aimee S. Weisner Corporate Vice President, General Counsel
Age: 44
Bio & Compensation  - Reuters
Christine Z. McCauley Corporate Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 51
Bio & Compensation  - Reuters
Bruce P. Garren Corporate Vice President - Public Affairs and Special Counsel
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Kehl Jr. Corporate Vice President - Strategy and Corporate Development
Age: 59
Bio & Compensation  - Reuters
Paul C. Redmond Corporate Vice President - Global Corporate Operations
Age: 49
Bio & Compensation  - Reuters
Carlyn D. Solomon Corporate Vice President - Critical Care and Vascular
Age: 50
Bio & Compensation  - Reuters
Patrick B. Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance